Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.42 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21217622 | 0.91 | ROCK2 (0.53) | MAOBNPC1MEN1KMT2AROCK2 | |
| SCHEMBL22967054 | 0.88 | ROCK2 (0.53) | NPC1EGFRROCK2CDK4CCND1 | |
| SCHEMBL24610278 | 0.87 | RET (0.48) | MAOBNPC1MEN1KMT2AEGFR | |
| SCHEMBL21198598 | 0.85 | ROCK2 (0.44) | MAOBNPC1MEN1KMT2AEGFR | |
| SCHEMBL21217913 | 0.81 | ROCK2 (0.54) | NPC1ROCK2ROCK1 | |
| SCHEMBL22967232 | 0.81 | RET (0.44) | MAOBEGFRRETSYKROCK2 | |
| SCHEMBL22966856 | 0.81 | ROCK1 (0.52) | NPC1MEN1KMT2AROCK2ROCK1 | |
| SCHEMBL21217619 | 0.81 | ROCK1 (0.52) | NPC1ROCK2ROCK1 | |
| SCHEMBL22966914 | 0.81 | ROCK1 (0.52) | NPC1ROCK2ROCK1 | |
| SCHEMBL21217908 | 0.79 | MEN1 (0.52) | MAOBNPC1MEN1KMT2AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
| EP-4026834-A1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Plc (GB) | 2022-07-13 | — | — | EP | disclosed |
| EP-3743420-B1 | HETEROCYCLYLAMINO-SUBSTITUTED TRIAZOLES AS MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA PLC (GB) | 2021-12-15 | — | — | EP | disclosed |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | REDX PHARMA LIMITED (GB) | 2021-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216386-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | MAOB 2505/4885NPC1 1504/4885MEN1 2942/4885 |
| US-20210038606-A1 | Modulators of Rho-associated Protein Kinase | ROCK2, ROCK1, RHOA | MAOB 2360/4885NPC1 1742/4885MEN1 2886/4885 |
| US-20230021916-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK2, ROCK1, RHOA | MAOB 2505/4885NPC1 1504/4885MEN1 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.